JCA PICO Prediction Services

Anticipate JCA Scope. Align Evidence Early.

Preparing for a Joint Clinical Assessment (JCA) under the EU HTA Regulation requires early clarity on likely PICO scope—Population, Intervention, Comparator, and Outcomes.

The JCA PICO Prediction Service from RTI Health Solutions helps life sciences companies anticipate how EU Member States will define assessment scope. This enables more focused evidence generation, reduced submission risk, and stronger reimbursement positioning.

Role of the PICO in the Assessment

diagram illustrating how PICOs inform data requirements and assessment framework in JCA

Why PICO Prediction Matters

JCA scope determines: 

  • Comparator selection
  • Indirect treatment comparison (ITC) strategy
  • Evidence generation priorities
  • Clinical development alignment
  • Reimbursement readiness

Misaligned scope assumptions can delay submissions and increase evidence gaps. Our structured, evidence-based approach helps mitigate that risk.

Our Approach: Expert-Led and Submission Focused

Effective PICO prediction requires more than mere analog analysis: it's a reflection of Member State–level needs and requires identification of real-world treatment patterns, validation, and integration with submission strategy.

Our approach combines:

  • Structured secondary research
  • AI-enabled landscape analysis
  • Country-level treatment pathway assessment
  • External clinician and payer validation
  • Integration with HTA and JCA submission strategy

Rather than relying solely on automated outputs, we provide predictions that are grounded in reality, are relevant, are informed by market insights, and stand up to scrutiny during HTA reviews.

Choose the Level of Insight Your Timeline Demands

Graphic showing three PICO prediction levels: PICO Light with rapid directional insight, PICO Plus with expert‑validated predictions, and PICO Advance with submission‑grade readiness.

3 Levels of JCA PICO Support

We offer a structured, AI-enabled 3-tiered approach to anticipating likely JCA PICO scope. Each level is designed to align with your development stage, geographic priorities, and evidence planning needs, from early strategic direction to submission-grade readiness.

PICO LightPICO PlusPICO Advance

Early directional insight

  • EU4 scope predictions
  • Secondary research and expert interpretation
  • Assessment of current and emerging comparators

Validated multicountry predictions

  • EU4 + 5 additional countries
  • Comparator and management trend analysis
  • External clinician and payer validation

Submission-grade prioritization

  • Prioritized PICO strategies across 15+ countries
  • Multicountry external validation
  • Research insights to inform evidence strategy
  • Preliminary ITC feasibility assessment
Ideal for early development and portfolio planningIdeal for phase 3 alignment and risk mitigationDesigned for JCA submission readiness

How We Differentiate

Integrated with HTA strategy

Our outputs align with Global Value Dossiers, HTA submissions, and evidence planning—not standalone analytics.

Human expertise + AI-enabled synthesis

We combine technology with therapeutic and payer insights to ensure contextual accuracy.

Multicountry validation

Predictions reflect real-world decision-making dynamics across EU markets.

Designed for Cross-Functional HTA Leadership

Early PICO clarity drives better cross-functional decision-making and stronger European launch readiness.

Our service is designed for:

  • Market access teams shaping reimbursement strategy
  • HEOR leaders guiding comparative evidence
  • Clinical development teams aligning trial design
  • Global value strategy leads overseeing EU HTA readiness

We support therapeutic programs at every stage of European market access preparation.

Meet Our Expert